Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast- 2027
DelveInsight Business Research LLP
Albany, NY -- (SBWire) -- 01/15/2019 --DelveInsight has announced the addition of the "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.
Report provides an overview of the disease and market size of PTCL for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report also covers the overview, treatment practices and PTCL forecasted epidemiology from 2018 to 2027, segmented by seven major markets.
Request for sample pages
Peripheral T-cell Lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin's Lymphomas (NHL) that develop from mature T-cells. PTCL is classified in accordance to the site of origin of the malignant T cell in the body as Nodal, Extranodal, Cutaneous and Leukemic. Most of the subtypes are rare and mainly 4 subtypes of PTCL- peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma (ALCL), Nasal NK/T-Cell Lymphoma and angioimmunoblastic T-cell lymphoma (AITL) account for about 75% of the PTCL cases. PTCL appears to be slightly more common in men than women.
PTCL comprises of about 10-15% of all NHL cases in United States and about 7.5-8% of total NHL cases in Japan. Approximately, 6000 new cases of PTCL are diagnosed every year in the United States. PTCL accounts for less than 10% of all diagnosed Non-Hodgkin's lymphoma cases in North America and Western Europe. Peripheral T-cell non-Hodgkin lymphoma (PTCL), not otherwise specified (NOS), is the most common PTCL. Subtype, accounting for at least 25% of PTCL.About 15% of pathologically diagnosed PTCL-NOS can be reclassified as angioimmunoblastic T-cell lymphoma (AITL), whereas in nearly 10% of Cases, a correct diagnosis of anaplastic large cell lymphoma (ALCL) or extranodal natural killer/T-cell lymphoma can be ruled out.
Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCLNOS) is the most common subtype of PTCL, accounting for about 36 percent of all PTCLs, as compared to other subtypes including Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL), and Cutaneous T-Cell Lymphomas (CTCL). Anaplastic Large Cell Lymphoma is rare, accounting for about one percent of all Non-Hodgkin Lymphoma (NHLs) and about 10 percent of all T-cell lymphomas (TCLs). Angioimmunoblastic T-Cell Lymphoma is a rare, aggressive PTCL that affects about 13 percent of all patients with PTCL in United States.
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
1. CerRx, Inc
2. Solasia Pharma
3. Genor Biopharma
4. Rafael Pharmaceuticals
and And many others
And many others
The report covers a descriptive overview of the PTCL, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the PTCL disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for PTCL are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted PTCL market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global PTCL market.
Media Relations Contact
Digital Marketing Specialist
View this press release online at: http://rwire.com/1118872